MX12880A - Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido - Google Patents

Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido

Info

Publication number
MX12880A
MX12880A MX1288088A MX1288088A MX12880A MX 12880 A MX12880 A MX 12880A MX 1288088 A MX1288088 A MX 1288088A MX 1288088 A MX1288088 A MX 1288088A MX 12880 A MX12880 A MX 12880A
Authority
MX
Mexico
Prior art keywords
stable
storage
human protein
procedure
preparation
Prior art date
Application number
MX1288088A
Other languages
English (en)
Inventor
Heinrich Woog
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of MX12880A publication Critical patent/MX12880A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
MX1288088A 1987-09-05 1988-08-31 Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido MX12880A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729863 DE3729863A1 (de) 1987-09-05 1987-09-05 Stabilisierte erythropoietin-lyophilisate

Publications (1)

Publication Number Publication Date
MX12880A true MX12880A (es) 1993-12-01

Family

ID=6335375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX1288088A MX12880A (es) 1987-09-05 1988-08-31 Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido

Country Status (29)

Country Link
US (1) US4992419A (es)
EP (1) EP0306824B1 (es)
JP (1) JPH0780782B2 (es)
KR (1) KR960009929B1 (es)
CN (1) CN1027224C (es)
AT (1) ATE77556T1 (es)
AU (1) AU610636B2 (es)
CA (1) CA1330301C (es)
CS (1) CS274681B2 (es)
DD (1) DD273004A5 (es)
DE (2) DE3729863A1 (es)
DK (1) DK174811B1 (es)
ES (1) ES2051806T3 (es)
FI (1) FI93517C (es)
GR (1) GR3005454T3 (es)
HK (1) HK89495A (es)
HU (1) HU202761B (es)
IE (1) IE60310B1 (es)
IL (1) IL87628A (es)
LV (1) LV10178B (es)
MX (1) MX12880A (es)
NO (1) NO178687C (es)
NZ (1) NZ225975A (es)
PH (1) PH25618A (es)
PL (1) PL157944B1 (es)
PT (1) PT88417B (es)
RU (2) RU2043118C1 (es)
UA (2) UA26123A (es)
ZA (1) ZA886528B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0582933A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
JP2000507912A (ja) * 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
PT986644E (pt) * 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
MXPA01010208A (es) 1999-04-09 2003-07-21 Johnson & Johnson Composiciones farmaceuticas de eritropoyetina.
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7253142B1 (en) * 1999-09-08 2007-08-07 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
CN1309416C (zh) * 2000-05-15 2007-04-11 霍夫曼-拉罗奇有限公司 新的药物组合物
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
AU2004244920B2 (en) * 2003-06-10 2009-07-23 Lg Chem, Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
WO2005032467A2 (en) * 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
DE102004011663B4 (de) 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
SI2328601T1 (sl) * 2008-08-15 2020-08-31 Ironwood Pharmaceuticals, Inc. Linaklotid vsebujoče formulacije za oralno dajanje
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011056850A2 (en) * 2009-11-03 2011-05-12 Ironwood Pharmaceuticals, Inc. Treatment of chronic constipation
WO2011090306A2 (en) * 2010-01-19 2011-07-28 Hanmi Holdings Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
WO2013025969A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
EA022327B1 (ru) * 2013-01-04 2015-12-30 Общество С Ограниченной Ответственностью "Рубикон" Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения
EP3125922B1 (en) 2014-03-29 2020-10-14 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of conjugated erythropoietin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
HUT41632A (en) * 1985-03-06 1987-05-28 Survival Technology Process for preparing agents for the enhancement of protein absorption

Also Published As

Publication number Publication date
IL87628A (en) 1993-07-08
NO883926D0 (no) 1988-09-02
CA1330301C (en) 1994-06-21
NO883926L (no) 1989-03-06
PL157944B1 (en) 1992-07-31
CS590188A2 (en) 1990-12-13
HUT47863A (en) 1989-04-28
IL87628A0 (en) 1989-01-31
PT88417A (pt) 1989-07-31
GR3005454T3 (es) 1993-05-24
EP0306824B1 (de) 1992-06-24
RU2043118C1 (ru) 1995-09-10
PT88417B (pt) 1992-10-30
JPS6471818A (en) 1989-03-16
NZ225975A (en) 1991-07-26
LV10178B (en) 1995-04-20
US4992419A (en) 1991-02-12
JPH0780782B2 (ja) 1995-08-30
FI93517B (fi) 1995-01-13
DD273004A5 (de) 1989-11-01
ATE77556T1 (de) 1992-07-15
DE3872334D1 (de) 1992-07-30
EP0306824A2 (de) 1989-03-15
IE60310B1 (en) 1994-06-29
RU2100032C1 (ru) 1997-12-27
HU202761B (en) 1991-04-29
HK89495A (en) 1995-06-16
DK174811B1 (da) 2003-12-01
NO178687B (no) 1996-02-05
AU2173988A (en) 1989-04-27
EP0306824A3 (en) 1990-01-31
FI884051A0 (fi) 1988-09-02
DE3729863A1 (de) 1989-03-16
AU610636B2 (en) 1991-05-23
KR960009929B1 (ko) 1996-07-25
IE882671L (en) 1989-03-05
NO178687C (no) 1996-05-15
FI884051A (fi) 1989-03-06
UA26123A (uk) 1999-06-07
PH25618A (en) 1991-08-08
KR890004718A (ko) 1989-05-09
ES2051806T3 (es) 1994-07-01
CN1031801A (zh) 1989-03-22
DK483188D0 (da) 1988-08-30
UA26855C2 (uk) 1999-12-29
PL274485A1 (en) 1989-04-17
ZA886528B (en) 1989-05-30
LV10178A (lv) 1994-10-20
DK483188A (da) 1989-03-06
FI93517C (fi) 1995-04-25
CN1027224C (zh) 1995-01-04
CS274681B2 (en) 1991-09-15

Similar Documents

Publication Publication Date Title
MX12880A (es) Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
AU1141288A (en) Production of proteins in active forms
DK0395287T3 (da) Tandbehandlingspræparater
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
HUT55598A (en) Fungicidal composition comprising new amino acid amide derivatives as active ingredient and process for producing the active ingredients
DE68920896D1 (de) N2-(1-Carboxy-3-phenylpropyl)-L-lysinderivate und Verfahren für die Herstellung von Lysinopril mit Hilfe dieser Verbindung.
EP0381504A3 (en) Improvements in and relating to guanidine derivatives
AU6724581A (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
BR9004693A (pt) Solucao aquosa,processo para aumentar a concentracao de proteina de uma proteina em uma solucao aquosa,e composicao farmaceutica
IT8820871A0 (it) Composizione farmaceutica che si accumula nella pelle e procedimento per la sua preparazione.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
EP0038153A3 (en) Modified allergens
IT9020615A1 (it) Composto con attivita' vasodilatatrice, procedimento per la sua preparazione e composizione farmaceutiche che lo contengono
IT8703667A0 (it) Procedimento per la produzione di in coadiuvante alimentare liquido per uso zootecnico,impianto che attua tale procedimento e coadiuvante alimentare cosi'ottenuto